Beryl Drugs Q4 Results
- BSE: 524606
- NSE: -
- ISIN: INE415H01017
- Sector: Biotechnology & Drugs
BSE
19.40
-1.00 (-4.90%)
-1.00 (-4.90%)Volume4.58 K
Updated: Fri 16 May, 2025 | 15:41:41
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Beryl Drugs Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 24 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 2.98 | 5.31 | -60.96% | 2.98 | N/A |
| Selling/ General/ Admin Expenses Total | 0.49 | 0.62 | -10.53% | 0.49 | N/A |
| Depreciation/ Amortization | 0.32 | 0.31 | 2.34% | 0.32 | N/A |
| Other Operating Expenses Total | -0.33 | 2.36 | 0.00% | -0.33 | N/A |
| Total Operating Expense | 3.50 | 5.12 | -51.23% | 3.50 | N/A |
| Operating Income | -0.52 | 0.19 | 0.00% | -0.52 | N/A |
| Net Income Before Taxes | -0.42 | 0.16 | 0.00% | -0.42 | N/A |
| Net Income | -0.35 | 0.05 | 0.00% | -0.35 | N/A |
| Diluted Normalized EPS | -0.68 | 0.10 | 0.00% | -0.68 | N/A |